Availability of FLT3 inhibitors: how do we use them?

Alexander E. Perl


The natural history of FLT3-mutated AML is changing after the approval of midostaurin for frontline therapy and gilteritinib for relapsed or refractory patients. Recently reported, positive randomized trials of the drugs gilteritinib, quizartinib, and sorafenib predict even wider use of FLT3 inhibitors going forward. FLT3 inhibitors now emerge as an important, if not indispensable, part of therapy for a large subset of high-risk patients.

  • Submitted January 8, 2019.
  • Accepted June 17, 2019.
View Full Text